SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

PRAX

Praxis Precision Medicines, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 16h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock's near-term catalyst path is binary: relutrigine PDUFA on Dec 27 and ulixacaltamide PDUFA on Jan 29. The EMERALD readout in Q4 adds another binary event. Monitor FDA advisory committee schedules and any pre-PDUFA briefing documents.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

PRAX drug pipeline →

relutrigine

▲ Bullish Named in this press release
Impact
Phase
Filed/PDUFA (NDA under priority review)
Time to market
PDUFA target action date is December 27, 2026. If approved, a U.S. launch could follow in early 2027.
Next catalyst
PDUFA date · Dec 27, 2026 41d

What to watchThe next binary catalyst is the PDUFA decision on December 27, 2026, roughly six weeks away. Approval would likely drive a significant re-rating given no approved therapies exist for SCN2A/SCN8A DEEs, while a CRL would pressure the stock. Also watch for EMERALD study topline results in broad DEEs (Q4 2026), which could expand the addressable market.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$332.97
T+0 close · Nov 9, 2026 · via day close
Latest settled
−6.82%
T+5 · $310.27
Vs SPY
−5.12%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $332.97entry
  2. T+1 · 7d ago +1.39%α +1.76% · $337.59
  3. T+5 · 16h ago −6.82%α −5.12% · $310.27
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Praxis Precision Medicines reported Q3 2026 net loss of $94.2M ($3.23 per share), wider than the $73.9M loss a year ago, with no revenue. The focus is on two upcoming PDUFA dates: relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027), plus an EMERALD readout in Q4 2026. Cash of $1.3B funds operations into 2028.

Key Financial Metrics

EPS
−$3.23
est −$3.63 · +11.0%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Net loss of $94.2M for Q3 2026 vs $73.9M in Q3 2025
  • GAAP EPS of ($3.23) vs consensus estimate of ($3.63), a beat
  • Cash and investments of $1.3B as of Sep 30, 2026, up from $926.1M at Dec 31, 2025
  • PDUFA target action date for relutrigine: Dec 27, 2026
  • PDUFA target action date for ulixacaltamide: Jan 29, 2027
  • EMERALD study topline results expected in Q4 2026
  • R&D expenses $64.2M vs $65.8M year-over-year
  • G&A expenses $42.7M vs $12.6M year-over-year, driven by commercial launch preparations
  • 27.9M shares outstanding as of Sep 30, 2026

Financial Impact

Net loss widened by $20.3M YoY; cash burn rate increased with G&A spending up $30.1M for launch readiness

net losscash positionoperating expenses

Risk Factors

  • FDA non-approval or complete response letter for either NDA
  • Negative or inconclusive EMERALD topline results
  • Cash burn accelerating with commercial buildout before revenue generation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398230

Track record

16 reports on PRAX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $332.97 Now $310.27 −6.82% settles Feb 5
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  5. Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
  7. Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
  9. Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
  10. May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026